# IBRX — ImmunityBio · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** IBRX  
**Sources:** 28  
**Published:** 2026-10-30  
**Canonical:** https://app.k3vl4r.com/research/deep-research-ibrx-immunitybio-catalysts-narrative-risks-10075

---

# ImmunityBio (IBRX) — Research Summary as of October 30, 2026

## Current Snapshot
As of the last trading session (October 29, 2026), IBRX closed around **$8.74–$8.81**, with a market capitalization of approximately **$9.26B** [[15]](https://tickernerd.com/stock/ibrx-forecast/), [[20]](https://stockanalysis.com/stocks/ibrx/), [[26]](https://finance.yahoo.com/quote/IBRX/). The stock trades within a 52-week range of **$1.95–$12.43** and has posted extraordinary recent returns — year-to-date around +341% and a 1-year total return near +261%, reflecting a massive run-up that has already priced in substantial optimism [[15]](https://tickernerd.com/stock/ibrx-forecast/). (Some sources cite higher figures, e.g., +382% YTD / +285% 1-year, but all point to the same conclusion of an aggressive rally) [[8]](https://finance.yahoo.com/healthcare/articles/immunitybio-ibrx-could-33-undervalued-090718252.html). The date is confirmed as of October 30, 2026 [[30]](https://www.nasdaq.com/market-activity/stocks/ibrx).

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-ibrx-immunitybio-catalysts-narrative-risks-10075 (free to sign up)._
